Skip to content

Boston Scientific

US · BSX #364 by market cap Listed 1970
41.98 -1.01 -2.35%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 7 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.2 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
95.58% -0.17pp
Institutions
1,910 -7
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund76.28%
Hedge Fund8.43%
Public Company3.71%
Government Pension Fund2.22%
Private Company1.68%
Sovereign Wealth Fund1.58%
VC/PE Fund0.41%
Endowment Fund0.33%
Insurance Company0.21%
Corporate Pension Plan0.30%
Other5.05%

Top holders as of 2026-09-30

BlackRock 8.66% · 125.56M sh
Vanguard Capital Management, LLC 7.11% · 103.09M sh
State Street Global Advisors 4.64% · 67.32M sh
PRIMECAP Management Company 4.04% · 58.62M sh
Capital Research 3.23% · 46.86M sh
Other 72.73%
Vanguard Portfolio Management, LLC 3.13% · 45.39M sh
MFS Investment Management 2.97% · 43.05M sh
Geode Capital Management, LLC 2.38% · 34.47M sh
FMR 2.13% · 30.95M sh
UBS Asset Management 2.03% · 29.44M sh
D. E. Shaw & Co., L.P. 1.76% · 25.46M sh
Arrowstreet Capital, Limited Partnership 1.96% · 28.47M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 38 buys · 11 sells

NameRoleStake
Michael Mahoney Chairperson & CEO 0.13%
Joseph Fitzgerald Executive VP & Group President of Cardiovascular 0.02%
Daniel Brennan Former Chief Financial Officer 0.01%
Arthur Crosswell Butcher Executive VP and Group President of MedSurg & Asia Pacific 0.01%
Jeffrey Mirviss Former Senior VP & President of Peripheral Interventions 0.00%
Charles Dockendorff Former Independent Director 0.00%
John Sununu Former Independent Director 0.00%
Vance Brown EVP, General Counsel & Corporate Secretary 0.00%
Jonathan Monson Chief Financial Officer 0.00%
David Wichmann Independent Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-03 Michael Mahoney Chairperson & CEO Other Acquisition +252,241 --
2026-10-31 Miriam O'sullivan -- Derivative Exercise and Sale -1,872 $41.98
2026-10-31 Miriam O'sullivan -- Derivative Exercise and Retained +1,999 --
2026-09-01 Padraig O'Connor -- Derivative Exercise and Sale -567 $48.37
2026-09-01 Padraig O'Connor -- Derivative Exercise and Retained +604 --
2026-08-24 Susan Morano Independent Director Open Market Acquisition +2,040 $49.22
2026-08-10 Emily Woodworth Senior VP, Global Controller & Chief Accounting Officer Acquisition Under Employee Benef +2,930 $51.19
2026-08-09 Jonathan Monson Chief Financial Officer Acquisition Under Employee Benef +9,908 $50.46
2026-08-04 David Habiger Independent Director Open Market Acquisition +2,100 $47.59
2026-08-03 David Habiger Independent Director Open Market Acquisition +1,182 $48.07–48.59
2026-08-02 Michael Mahoney Chairperson & CEO Open Market Acquisition +186,240 $48.33
2026-08-02 Michael Mahoney Chairperson & CEO Acquisition Under Employee Benef +22,119 $48.43
2026-07-30 Edward Ludwig Lead Independent Director Open Market Acquisition +5,000 $45.48
2026-07-30 Joseph Fitzgerald Executive VP & Group President of Cardiovascular Acquisition Under Employee Benef +64,198 $46.73
2026-06-30 Jonathan Monson Chief Financial Officer Derivative Exercise and Sale -1,010 $43.06
2026-06-30 Jonathan Monson Chief Financial Officer Derivative Exercise and Retained +1,077 --
2026-05-27 Michael Mahoney Chairperson & CEO Other Disposition -386,755 --
2026-05-19 Edward Ludwig Lead Independent Director Open Market Acquisition +3,580 $56.68
2026-05-19 Cheryl Pegus Independent Director Open Market Acquisition +1,770 $56.49
2026-05-19 David Habiger Independent Director Open Market Acquisition +4,450 $55.92–56.95

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.

Boston Scientific discussion 0 comments

Add a comment